Wed, November 24, 2021
Tue, November 23, 2021
Mon, November 22, 2021
Sun, November 21, 2021
Sat, November 20, 2021
Fri, November 19, 2021
Thu, November 18, 2021
Wed, November 17, 2021
Tue, November 16, 2021

Evan Seigerman Initiated (VRTX) at Hold and Held Target at $202 on, Nov 19th, 2021


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. old-and-held-target-at-202-on-nov-19th-2021.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Evan Seigerman of BMO Capital, Initiated "Vertex Pharmaceuticals Incorporated" (VRTX) at Hold and Held Target at $202 on, Nov 19th, 2021.

Evan has made no other calls on VRTX in the last 4 months.



There are 7 other peers that have a rating on VRTX. Out of the 7 peers that are also analyzing VRTX, 1 agrees with Evan's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Paul Matteis of "Stifel" Downgraded from Strong Buy to Hold and Decreased Target to $213 on, Thursday, September 9th, 2021


These are the ratings of the 6 analyists that currently disagree with Evan


  • Brian Abrahams of "RBC Capital" Maintained at Buy with Increased Target to $250 on, Wednesday, November 3rd, 2021
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy and Held Target at $275 on, Tuesday, November 2nd, 2021
  • Brian Skorney of "Baird" Maintained at Buy and Held Target at $240 on, Tuesday, October 19th, 2021
  • Matthew Harrison of "Morgan Stanley" Downgraded from Hold to Sell and Held Target at $202 on, Tuesday, September 7th, 2021
  • Edward Tenthoff of "Piper Sandler" Maintained at Buy with Increased Target to $323 on, Friday, July 30th, 2021
  • Geoffrey Porges of "SVB Leerink" Maintained at Sell with Increased Target to $175 on, Friday, July 30th, 2021

Publication Contributing Sources